Keywords:
Kidney, CT, Contrast agent-intravenous, Cancer
Authors:
X. Shen1, L. Zhou2, L. Cheng2; 1Shen Zhen/CN, 2shenzhen/CN
DOI:
10.1594/ecr2018/C-1349
Results
Tumor appearances were highly variable with intra-tumoural heterogeneity seen in Oncocytomas (6/6) (Fig.
1),
LPAML (2/8) (Fig.
2),
PRCC (6/8) (Fig.
3) and ChRCC (2/6) (Fig.
4).
Tumor necrosis was more common in PRCC (6/8) compared to ChRCC (2/6),
Oncocytoma (2/6) and LPAML (1/8).
Central scars were only present in Oncocytomas (6/6) and none of the other three tumors.
Abnormal vascularity and intra-tumoural vessels could be seen in malignant tumours (PRCC and ChRCC) (7/14) (Fig.
4); malformed vessels could be seen in LPAML (5/8) (Fig.
2).
Distinct enhancement kinetics were seen between benign (Oncotyoma and LPAML) and malignant (PRCC and ChRCC) tumors.
Benign tumors demonstrated rapid enhancement on corticomedullary followed by slow washout on parenchyma and excretory phases whereas gradual continuous increase in enhancement through corticomedullary and parenchyma phases was seen in malignant tumors followed by plateauing/mild washout (Table 1).No significant difference in enhancement kinetics was seen between the two benign or malignant tumors.